{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:30:50Z","timestamp":1787729450213,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["6NU62PS924769"],"award-info":[{"award-number":["6NU62PS924769"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Maryland Department of Health, United States"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Addressing xylazine harms are now a critical harm reduction priority, but relatively little epidemiological information exists to determine prevalence, magnitude, and correlates of xylazine use or related outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a rapid behavioral survey among people who inject drugs (<jats:italic>n<\/jats:italic>\u2009=\u200996) in Baltimore November\u2013December 2022. Using a novel indicator of self-reported presumed xylazine effects, we examined prevalence and sociodemographic correlates of past year presumed xylazine effects and association with overdose and wound-related outcomes. Chi-square and descriptive statistics were used to examine bivariate associations overall and separately for those who reported xylazine by name and by reported fentanyl use frequency.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Almost two-thirds (61.5%) reported experiencing xylazine effects. There were no differences by socio-demographics, but xylazine effects were more commonly reported among those who reported injecting alone (66% vs 38%%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.007) and daily fentanyl use (47% vs 24% <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.003). Those reporting xylazine exposure was three times as likely to report overdose (32% vs 11%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.03) and twice as likely to have used naloxone (78% vs 46%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.003). They also more commonly reported knowing someone who died of an overdose (92% vs 76%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.09) and to report an abscess requiring medical attention (36% vs 19%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.80). These associations were higher among respondents who specifically named xylazine and those who used fentanyl more frequently, but fentanyl frequency did not fully explain the heightened associations with xylazine effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study provides insight into the scope of xylazine exposure and associated health concerns among community-based PWID and suggests measures that may be instrumental for urgently needed research.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-00940-z","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T17:02:35Z","timestamp":1705942955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Reported xylazine exposure highly associated with overdose outcomes in a rapid community assessment among people who inject drugs in Baltimore"],"prefix":"10.1186","volume":"21","author":[{"given":"Danielle","family":"German","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Genberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Sugarman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Saloner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Glick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Gribbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"940_CR1","unstructured":"FDA alerts health care professionals of risks to patients exposed to xylazine in illicit drugs [press release]. November 8, 2022 2022."},{"key":"940_CR2","unstructured":"Drug Enforcement Administration. DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine 2023 [Available from: https:\/\/www.dea.gov\/alert\/dea-reports-widespread-threat-fentanyl-mixed-xylazine#:~:text=United%20States%20Drug%20Enforcement%20Administration,-Search&text=."},{"key":"940_CR3","unstructured":"Office of National Drug Control Policy. Biden-\u2060Harris Administration Designates Fentanyl Combined with Xylazine as an Emerging Threat to the United States 2023 [updated April 12, 2023. Available from: https:\/\/www.whitehouse.gov\/ondcp\/briefing-room\/2023\/04\/12\/biden-harris-administration-designates-fentanyl-combined-with-xylazine-as-an-emerging-threat-to-the-united-states\/."},{"issue":"37","key":"940_CR4","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.15585\/mmwr.mm7037a4","volume":"70","author":"M Kariisa","year":"2021","unstructured":"Kariisa M, Patel P, Smith H, Bitting J. Notes from the field: xylazine detection and involvement in drug overdose deaths\u2014United States, 2019. MMWR Morb Mortal Wkly Rep. 2021;70(37):1300\u20132.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"940_CR5","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez N, Vargas Vidot J, Panelli J, Col\u00f3n H, Ritchie B, Yamamura Y. GC-MS confirmation of xylazine (Rompun), a veterinary sedative, in exchanged needles. Drug Alcohol Depend. 2008;96(3):290-3","DOI":"10.1016\/j.drugalcdep.2008.03.005"},{"issue":"3","key":"940_CR6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11524-011-9662-6","volume":"89","author":"JC Reyes","year":"2012","unstructured":"Reyes JC, Negr\u00f3n JL, Col\u00f3n HM, Padilla AM, Mill\u00e1n MY, Matos TD, et al. The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico. J Urban Health. 2012;89(3):519\u201326.","journal-title":"J Urban Health"},{"issue":"Suppl 1","key":"940_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/00333549071220S106","volume":"122","author":"KM Gallagher","year":"2007","unstructured":"Gallagher KM, Sullivan PS, Lansky A, Onorato IM. Behavioral surveillance among people at risk for HIV infection in the U.S.: the National HIV Behavioral Surveillance System. Public Health Rep. 2007;122(Suppl 1):32\u20138.","journal-title":"Public Health Rep"},{"issue":"1","key":"940_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1525\/sp.2002.49.1.11","volume":"49","author":"D Heckathorn","year":"2002","unstructured":"Heckathorn D. Respondent driven sampling II: Deriving valid population estimates from chain referral samples of hidden populations. Soc Probl. 2002;49(1):11\u201334.","journal-title":"Soc Probl"},{"key":"940_CR9","doi-asserted-by":"publisher","first-page":"104154","DOI":"10.1016\/j.drugpo.2023.104154","volume":"120","author":"T Quijano","year":"2023","unstructured":"Quijano T, Crowell J, Eggert K, Clark K, Alexander M, Grau L, et al. Xylazine in the drug supply: emerging threats and lessons learned in areas with high levels of adulteration. Int J Drug Policy. 2023;120:104154.","journal-title":"Int J Drug Policy"},{"key":"940_CR10","unstructured":"Drug Enforcement Administration. The growing threat of xylazine and its mixture with illicit drugs.  October 2022."},{"key":"940_CR11","unstructured":"National Harm Reduction Coalition. Xylazine in the drug supply. 2022."},{"issue":"9","key":"940_CR12","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1111\/add.16200","volume":"118","author":"C Bharat","year":"2023","unstructured":"Bharat C, Webb P, Wilkinson Z, McKetin R, Grebely J, Farrell M, et al. Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis. Addiction. 2023;118(9):1624\u201348.","journal-title":"Addiction"},{"issue":"1","key":"940_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12954-023-00879-7","volume":"20","author":"CM Zagorski","year":"2023","unstructured":"Zagorski CM, Hosey RA, Moraff C, Ferguson A, Figgatt M, Aronowitz S, et al. Reducing the harms of xylazine: clinical approaches, research deficits, and public health context. Harm Reduct J. 2023;20(1):141.","journal-title":"Harm Reduct J"},{"issue":"4","key":"940_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1136\/injuryprev-2020-043968","volume":"27","author":"J Johnson","year":"2021","unstructured":"Johnson J, Pizzicato L, Johnson C, Viner K. Increasing presence of xylazine in heroin and\/or fentanyl deaths, Philadelphia, Pennsylvania, 2010\u20132019. Inj Prev. 2021;27(4):395\u20138.","journal-title":"Inj Prev"},{"issue":"17","key":"940_CR15","doi-asserted-by":"publisher","first-page":"458","DOI":"10.15585\/mmwr.mm7217a2","volume":"72","author":"E Russell","year":"2023","unstructured":"Russell E, Sisco E, Thomson A, Lopes J, Rybak M, Burnett M, et al. Rapid analysis of drugs: a pilot surveillance system to detect changes in the illicit drug supply to guide timely harm reduction responses\u2014eight syringe services programs, Maryland, November 2021-August 2022. MMWR Morb Mortal Wkly Rep. 2023;72(17):458\u201362.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"13","key":"940_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.15585\/mmwr.mm7113a3","volume":"71","author":"N Chhabra","year":"2022","unstructured":"Chhabra N, Mir M, Hua MJ, Berg S, Nowinski-Konchak J, Aks S, et al. Notes from the field: xylazine-related deaths\u2014cook county, Illinois, 2017\u20132021. MMWR Morb Mortal Wkly Rep. 2022;71(13):503\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"940_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12954-021-00546-9","volume":"18","author":"JM Bowles","year":"2021","unstructured":"Bowles JM, McDonald K, Maghsoudi N, Thompson H, Stefan C, Beriault DR, et al. Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications. Harm Reduct J. 2021;18(1):104.","journal-title":"Harm Reduct J"},{"issue":"26","key":"940_CR18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.15585\/mmwr.mm7226a4","volume":"72","author":"M Kariisa","year":"2023","unstructured":"Kariisa M, O\u2019Donnell J, Kumar S, Mattson CL, Goldberger BA. Illicitly manufactured fentanyl-involved overdose deaths with detected xylazine\u2014United States, January 2019-June 2022. MMWR Morb Mortal Wkly Rep. 2023;72(26):721\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"940_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/15563650.2022.2159427","volume":"61","author":"JS Love","year":"2023","unstructured":"Love JS, Levine M, Aldy K, Brent J, Krotulski AJ, Logan BK, et al. Opioid overdoses involving xylazine in emergency department patients: a multicenter study. Clin Toxicol (Phila). 2023;61(3):173\u201380.","journal-title":"Clin Toxicol (Phila)"},{"key":"940_CR20","doi-asserted-by":"crossref","unstructured":"Spadaro A, O'Connor K, Lakamana S, Sarker A, Wightman R, Love JS, et al. Self-reported xylazine experiences: a mixed methods study of reddit subscribers. medRxiv. 2023.","DOI":"10.1101\/2023.03.13.23287215"},{"key":"940_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.04.009","author":"A Bishnoi","year":"2023","unstructured":"Bishnoi A, Singh V, Khanna U, Vinay K. Skin ulcerations caused by xylazine: a less-known entity. J Am Acad Dermatol. 2023. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.009.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"940_CR22","doi-asserted-by":"publisher","first-page":"S263","DOI":"10.1097\/00002030-199301001-00037","volume":"7","author":"SR Friedman","year":"1993","unstructured":"Friedman SR, de Jong W, Wodak A. Community development as a response to HIV among drug injectors. AIDS. 1993;7(Suppl 1):S263\u20139.","journal-title":"AIDS"},{"issue":"1\u20132","key":"940_CR23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3109\/10826080903080656","volume":"45","author":"J Dickson-Gomez","year":"2010","unstructured":"Dickson-Gomez J. Can drug users be effective change agents? Yes, but much still needs to change. Subst Use Misuse. 2010;45(1\u20132):154\u201360.","journal-title":"Subst Use Misuse"},{"issue":"1","key":"940_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12954-022-00693-7","volume":"19","author":"AV Schlosser","year":"2022","unstructured":"Schlosser AV, Hoffer LD. \u201cI don\u2019t go to funerals anymore\u201d: how people who use opioids grieve drug-related death in the US overdose epidemic. Harm Reduct J. 2022;19(1):110.","journal-title":"Harm Reduct J"},{"issue":"2","key":"940_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/jurban\/jtg022","volume":"80","author":"S Darke","year":"2003","unstructured":"Darke S, Hall W. Heroin overdose: research and evidence-based intervention. J Urban Health. 2003;80(2):189\u2013200.","journal-title":"J Urban Health"},{"issue":"3","key":"940_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1001\/jama.2022.10815","volume":"328","author":"R Gupta","year":"2022","unstructured":"Gupta R, Holtgrave DR. A national tracking system for nonfatal drug overdoses. JAMA. 2022;328(3):239\u201340.","journal-title":"JAMA"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00940-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-00940-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00940-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T17:09:23Z","timestamp":1705943363000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-00940-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["940"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-00940-z","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"assertion":[{"value":"18 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was determined to be consistent with public health surveillance purposes under 45 CFR 102(I)(2) by the Johns Hopkins Bloomberg School of Public Health and Maryland Department of Health Institutional Review Boards. All participants completed informed consent procedures and provided consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}